Screener
Guardant Health GH Q2 2026 earnings
Reported July 30, 2026 · After market close
Revenue$335.0MBeat by $20.7M
EPS-$0.90Miss by $0.14
Revenue estimate$314.2M
EPS estimate-$0.76
“Growth was fueled by strong oncology volume, with acceleration across every product. The landmark FDA approval of Guardant360 Liquid CDx further strengthens our portfolio and positions us to drive sustained growth in the years ahead.”
Next report
Oct 28, 2026 (in 2 months)Revenue estimate$350.1M
EPS estimate-$0.28
Valuation & ratios
Valuation
as of 08/27/26Versus estimates
Revenue
Diluted EPS
FAQ
- When did Guardant Health report Q2 2026 earnings?
- Guardant Health (GH) reported Q2 2026 earnings on July 30, 2026 after market close.
- What were Guardant Health's Q2 2026 revenue and EPS?
- Guardant Health reported revenue of $335.0M and eps of $-0.90 for Q2 2026.
- Did Guardant Health beat estimates in Q2 2026?
- Revenue beat the consensus estimate of $314.2M by $20.7M. EPS missed the consensus estimate of $-0.76 by $0.14.
- How did Guardant Health's Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 44.3% from $232.1M a year earlier and eps declined 104.5% from $-0.44.
- Where can I find Guardant Health's Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001576280-26-000036) and the 10-Q periodic report (0001576280-26-000037) directly on SEC EDGAR. The filing index links above go to sec.gov.
